Inositec
Therapeutic engineering of small molecules.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | $21.5m Valuation: $21.5m | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1 % | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Inositec is a biotechnology company specializing in the therapeutic engineering of small molecules. The company operates in the pharmaceutical and healthcare market, focusing on drug discovery and development. Utilizing its proprietary Inositune platform, Inositec modifies inositol hexaphosphate (IP6), a natural substance found in all eukaryotic cells, to create molecules with enhanced drug-like properties. These molecules are aimed at addressing unmet medical needs, particularly in the treatment of chronic diseases. Inositec serves pharmaceutical companies and healthcare providers, offering them innovative solutions for drug development. The company's business model revolves around research and development, partnering with other pharmaceutical firms, and licensing its technology. Revenue is generated through these partnerships, licensing agreements, and potential future sales of developed drugs.
Keywords: biotechnology, drug discovery, small molecules, inositol hexaphosphate, IP6, pharmaceutical, healthcare, chronic diseases, Inositune platform, therapeutic engineering.